Evidence map›Paper›PMID 30312579›Full record

Observational studyAmerican journal of ophthalmology2019

Natural History Study of Retinal Structure, Progression, and Symmetry Using Ellipzoid Zone Metrics in RPGR-Associated Retinopathy.

James J L Tee, Yesa Yang, Angelos Kalitzeos, Andrew Webster, James Bainbridge, Michel Michaelides

Registry-linked trialOpen access · hybridAbstract readObservational Study
In one paragraph

Observational study in American journal of ophthalmology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05537220 (NAC Attack, A Phase III, Multicenter, Randomized, Parallel, Double Masked, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients With Retinitis Pigmentosa), which is not on this map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05537220 phase3active not recruitingnot on this mapstarted 2023, after this paper: background citation

NAC Attack, A Phase III, Multicenter, Randomized, Parallel, Double Masked, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients With Retinitis Pigmentosa

TypeinterventionalSponsorJohns Hopkins UniversityRan2023 to 2030Enrolled485ConditionsRetinitis PigmentosaArmsN-acetylcysteine, Placebo
3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 61 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Gene therapy for choroideremia: progress, potential and pitfalls.Expert opinion on biological therapy · 2025
    Review
  9. Long-term natural history of ellipsoid zone width inThe British journal of ophthalmology · 2025
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. The British journal of ophthalmology · 2024
    Article
  15. Cold Spring Harbor perspectives in medicine · 2023
    Review
  16. Article
  17. Retinitis Pigmentosa: Current Clinical Management and Emerging Therapies.International journal of molecular sciences · 2023
    Review
  18. Article
  19. Article
  20. A Natural History Study ofJournal of clinical medicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

James J L TeeUniversity College London Institute of Ophthalmology and Moorfields Eye Hospital, London, United Kingdom.
Yesa YangUniversity College London Institute of Ophthalmology and Moorfields Eye Hospital, London, United Kingdom.
Angelos KalitzeosUniversity College London Institute of Ophthalmology and Moorfields Eye Hospital, London, United Kingdom.
Andrew WebsterUniversity College London Institute of Ophthalmology and Moorfields Eye Hospital, London, United Kingdom.
James BainbridgeUniversity College London Institute of Ophthalmology and Moorfields Eye Hospital, London, United Kingdom.
Michel MichaelidesUniversity College London Institute of Ophthalmology and Moorfields Eye Hospital, London, United Kingdom. Electronic address: michel.michaelides@ucl.ac.uk.
Moorfields Eye Hospital NHS Foundation Trust · GBUniversity College London · GB

Funding

Department of Health NIHR-RP-011-003Medical Research Council G0902206Wellcome Trust 099173/Z/12/Z
6 · The paper itself

Abstract

purposeThis is a quantitative study of retinal structure, progression rates, and interocular symmetry in retinitis pigmentosa GTPase regulator gene (RPGR)-associated retinopathy using spectral-domain optical coherence tomography (OCT).

designProspective, observational cohort study.

methodsThirty-eight subjects at Moorfields Eye Hospital in London were assessed with 2 spectral-domain OCT-derived ellipzoid zone (EZ) metrics with repeatability assessments. EZ width (EZW) measurements were made on transfoveal line scans. En face images of the EZ area (EZA) were generated from high-density macular volume scans and were quantified. Baseline size, progression rate, symmetry, associations with age and genotype, and baseline structure-function correlation were investigated.

resultsBaseline EZW and EZA measurements were 1963.6 μm and 3.70 mm

conclusionsEZ metrics are sensitive structural biomarkers for measuring residual extent and progression in RPGR-associated retinopathy. Our elucidation of the natural history will provide clinicians and patients with more knowledge about the condition and inform the design and interpretation of interventional trials.

Indexed as

Eye ProteinsRetinaRetinitis PigmentosaAdolescentAdultBiomarkersChildCohort StudiesDisease ProgressionExonsFemaleHumansMaleOpen Reading FramesProspective StudiesTomography, Optical CoherenceBiomarkersEye ProteinsRPGR protein, human

Identifiers

PMID30312579
PMCPMC6355316
OpenAlexW2895962596

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.